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U&ctives. This study sought to compare the relation hehveen 
smoking and the -M-day and 6-month outcome after acute myn- 
cardial inlarction in an Israeli nationwide survey. 
Buckgmund. Studies before and during the thmmbolytic era 
reported similar or lower early mortality after acute myomrdial 
infarction in smokers than in nonsmokers. This Rnding is intrigu- 
ing and may be misleadinlt because numemuj epidemiolotjc 
studies have clearly shown that smoking is an independent risk 
factnr for athemsclemsis, myocardial infarctinn and death. 
M&I&. The study cohort comprised 999 consecutive patients 
with an acute myocardiol infarction from a prospective nationwide 
survey conducted during January and February I!84 in all 
comnarv care units opemting in Israel. The pmgnosis of 367 
patients (37%) who wet- smokers tcurrent smokers and those who 
smoked up to I month before admission) was compared with that 
nf 632 nnnsmnkers (past smokers or those who never smoked). 
Resullu. Smokers were un average 1U years younger and were 
more frequently men and patients with a family history ,of 
coronary heart disease and inferior infarction and less frequently 
patients with a previous infarction or a history of angina, hyper- 
tension and diabetes than nonsmokers. Smokers also had a lower 
Dcspitc the fact th:t literally all epidemiologic studies have 
shown th;,t smoking is an independent risk factor for athero- 
sclerosis. acute myocardial infarction and death (l-3), some 
investigators (4-h) have reported a lower in-hospital mortality 
rate after myocardial infarction in smokers than nonsmokers. 
Surprisingly. smoking emerged as an independent predictor of 
hcttcr prognosis after acute myocardial infarction in the prc- 
thromholytic (45) and thromholytic eras (h-7). A prssihlc 
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incidence of congestive heart failure on adu~ission or duriw the 
hospital period. Thmmhoiytic therapy (49% vs. 40%, p < 0.01) 
and aspirin (89% vs. W%, p c 0.001) were admiuistcred more 
frequently in smokers than wnstuokers. The crude M-day (6.W 
vs. 15.7%) and cumulative &munth (7.9% vs. 215%) mortality 
rates were signitisantly lower tp < 0.0001 for both) in smokers 
than nonsmokers, respectively. However, after adjustment fur age. 
baseline characterlslies, thmmbolytic therapy and invasive mm- 
nary prrxedures, the lower 30-&y (odds ntio [OR] 0.75, 95% 
mnfidence interval ICI] 0.43 to 1.29, p = OJO) aud Cmoath 
(hazard ratio O.&l,%% CI 0.54 to 130, p = 0.42) mortality rates 
in smokers and uousmokers were uot siguitiuatly dikent. The 
model had a power olO.80 for OR 050, &II rlpba 0.1. 
Condusk. In our uatiouwide survey, tbe see&g& better 
protumsis of smokers early after acute q yoeardial infamtiw was 
no longer evident after adjustmeut tar baseliue ad clinical 
variables and may be explained by their younger age and a mom 
favorable risk profile. Smukers develop acute myocardial iafarc- 
tion a decade earlier than nonsmokers. Warts to lower tbe 
prevalence nf smokinp! should ccmtinue. 
(1 Am CoU C&id N96;28:15&Ll3) 
explanation for this apparent paradox was forwarded hy Ock- 
cne and Ockene (8) who hypothesized that smokers develop 
ing acute myocardial infarction are younger, have a more 
benign risk factor profile on admission and consequently have 
lower morhidity and mortality rates than nonsmokers. Recent 
studies from the thromhrlytic era (Y-l I) have shown that a 
bcttcr Thrombolysis in Myocardial Infarction (TIMI) flow 
grade is achieved after thrombolysis in smokers, suggesting 
that among smokers, thrombogenicity plays a greater role than 
in nonsmokers in the pathophysiology of acute myocardial 
infarction. 
Stimulated by thesepublications, we compared the early 
and (j-month prognosis of.smoken and nonsmokers among 
I ,012 consecutive patients with. acute myocardial infarction 
from a. prospective nationwide survey conducted during a 
2-month period in early 1994 in all 25 coronary care units in 
Israel. Our survey also enabled us to compare the baseline 
characteristics. management and outcome of smoken with and 
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without thrombolysis and thereby to assess the mechanisms 
underlying the better prognosis among smokers. 
Methods 
Palknls. A nationwide prospective survey was performed 
during a 2-month period (January and February 1994) in all 25 
coronary care units operating in Israel. Demographic, histnri- 
cal and clinical data were collected on special forms for all 
1,012 participants. Thirteen patients with incomplete data were 
excluded from the analysis. The diagnosis of acute myocardial 
infarction was based on the presence of two of the following: 
pain suggestive of myocardiel infarction lasting for at least 
30 min; unequivocal new electrocardiographic (ECG) alter- 
ations (Q/OS or ST-T segment or both, and T wave changes); 
or increase of at least two of the three serum cardiac enzymes 
(creatine kinase, aspartate aminotransferase and lactate dehy- 
drogenase) to more than 1.5 times the upper normal limit, or 
concomitant increase in creatine kinase (CK) and MB isoen- 
xyme. Cunrnf sm&rs were defined as patients who were 
smoking or had quit smoking within 1 month before admission. 
Nonsmokers were defined as patients who had either never 
smoked or had stopped smoking > 1 month before admission. 
Thirtyday and 6-month mortality was assessed from the 
medical charts and by matching the identification number of 
patients with the Israeli National Population Registry. 
Statistical raalysis. All analyses were performed using 
SAS statistical software (12). Chi-square and I tests were used 
to determine the significance of the differences between pro- 
portions and mean values, respectively, where appropriate. 
Results of continuous variables are -eported as mean value -t 
SD. so-sided p values are reported. 
A direct age adjustment (95% confidence interval [Cl]) 
was performed to compare mortality rates between smokers 
and nonsmokers. To compare 30day mortality in smokers and 
nonsmokers in terms of odds ratio ([OR] with 95% Cl; where 
nonsmokers were the reference group, OR ,= 1). a stepwise 
logistic regression analysis (SAS Logistic Procedure) was per- 
formed, adjusting for age, gender, diabetes, hypertension, 
family history of coronary artery disease, history of angina. 
previous infarction, anterior Q wave during the index infarc- 
tion, systolic blood pressure ~100 mm Hg, heart rate >100 
oeats/min and Killip class ~11 on admission, thmmbolytic 
Table 1. Baseline Characteristics of Smokers and Nonsmokers After 
Acute Mvocardial Infarction 
Smokcn 
(n = 367) 
Nonsmokers 
(n = 632)’ p value 
Men 
Age (:rl 
Prior MI 
Prior angina 
H>prrtcnsion 
Diahetcs 
Hypercholes!eralcmia 
Family history of CAD 
Prior CABG 
Prior PTCA 
Prior stroke 
Ml typeJocation* 
Anterior 0 wan 
Inferior Q wdvc 
Later31 0 wave 
Non-Q wave 
334 (91) 
57 z 12 
u6 (3) 
72 (Xl) 
107 (29) 
a (.lY) 
YY (77) 
79 (22) 
10 (3) 
.387 (bl) 
lIlz11 
204 (33) 
183 (29) 
311(W) 
X3 (34) 
144 (3) 
52 (U) 
24 (4) 
14 (4) 
109 (31) 
1.W (361 
10 (3) 
I IS (32) 
42 (7) 
1qu (311 
180 (?Y) 
10 (2) 
236 (38) 
< 0.m1 
O.oM)l 
O.oo! 
0.001 
< 0.00(31 
< O.Wnl 
II.14 
O.aMI 
0.37 
0.40 
o.ob 
0.0s 
‘Determined in 365 smokers and in 629 nonsmokers. Data presented are 
mean value + SD or numhcr (5) of p&m&. CABG = amnary artery bypass 
graft surgcly: CAD = zoronary artcry di!ea..: MI = myocardial infarction: 
PTCA = percutaneous transluminal coronary angiophsty. 
therapy and invasive coronary procedures (coronary angiogra- 
phy, coronary angioplasty and coronary artery bypass grafting) 
during the hospital period. A stepwise Cox proportional haa- 
ards regression model (SAS PHREG Procedure) adjusting for 
the same variables and for in-hospital complications. such as 
congestive heart failure and paroxysmal atrial fibrillation. was 
used to compare cumulative 6-month mortality in smokers 
versus nonsmokers in terms of hazard ratio ([HR] and 95% CI; 
where nonsmokers were the reference gmup, HR = 1). A 
variable was allowed to enter into the model if it made a 
significant contribution at the 0.10 level of significance and was 
removed if after subsequent addition of other variables to the 
model, it no longer made a contribution at the 0.15 level of 
significance. The sample size was large enough to produce a 
power of 0.8, if the OR for smokers to nonsmokers is 0.50, 
under a type 1 error of alpha = 0.1. 
Unadjusted survival curves were constructed using the 
method of Kaplan-Meier. The significance of the difference 
between the survival curves was assessed by the log-rank test 
(SAS Lifetest Pnxedure). Adjusted survival curves were pro- 
duced using variables entered into the best selected Cox model 
(SAS PHREG Procedure). 
Results 
6aseiine rhulctcristks. ,The baseline characteristics of 
999 patients ‘tith acute mjroeardial infarction- participating in 
the survey, including 367 (37%) smokers and 632 nonsmokers, 
‘are presented in Table 1. Smokers were on average 10 years 
younger (57 2 12 vs. 67 f: 11 years, p < O.tMOl): and were 
more frequently menc patients with a family history of coronary 
artery disease and Xerior infarction and less frequently pa- 
II.‘4 
0 IY)l 
II.IWHll 
Il.‘G 
(I.Wll3 
(IM 
0.5 I 
No 
0sYHll 
lLllcn,l 
rrsc 
:I.&9 
1 .IYl 
II.Jc) 
tienth with 3 previous infarction. a history of angina. stroke, 
hypertension and diahetes. 
In-hospital complications and management. On admis- 
sion. smokers had a better Killip class and lower heart rate 
than nonsmokers (Tat&! 2). Congestive heart failure. shock, 
severe mitral regureiration! paroxysmal atrial fibrillation and 
new bundle branch block were significantly less frequent 
among smokers than nonsmokers. although peak CK- 
estimated inf;:r;t size was similar in both groups (Table 2). 
i”onsmokcrs were more frequently treated with digitalis, 
;mgiotenc;n-converting enzyme inhibitors and diuretic drugs 
and Ir:,s frequently with calcium ant. gonists. thrombolytic 
thcripg. hcparin and aspirin than were smokers (Table 3). 
C,lronav angiography and coronary artcry bypass graft surgery 
were performed in similar proportions in both groups, whereas 
smokers more often underwent coronary angioplasty (Table 3). 
Mortality. The crude 3Wday mortality rate was significantly 
lower in smokers than nonsmokers (6.0% vs lS.7??. respcc- 
tivcly, p L< NOOI). However, after direct age adjustment. the 
W-day morlalily rates were not significantly ditfercnt belween 
smokers (8.W, 9.5’;; <‘I 5.0% to 12.5%) and nonsmokers 
(13.SG, 955 Cl II.O% to 16.0%,) (Table 4). Similarly, after 
adjusting for age and other baseline characteristics, thrombo- 
lytic therapy and invasive coronary procedures (see Methods), 
the lower 30-day mortality iate in stibkers was not of stzitistical 
significance (OR 0.7595% CI 0.43 to 1.29, p = 0.3O):(Tahle 4). 
Other variables entered (in.dccreasing order) into the final 
stepwise model were Killip class 211 on admission (OR 5.92, 
95% CI 3.69 to 9.47). age (l-year increment [OR 1.05,95% CI 
1.03 to 1.081). diabetes (OR 2.05, 95% CI 1.31 to 3.19) and 
invasive corona? procedures (,mgiography, coronav angio- 
plasty or h-ypass surgery [OR 0.N. YWi CI 0.2(i to 1 .W]). 
Th& cumulative 6-month crude mortality rate was signili- 
cantly lower in smokers than nonsmokers (7.Y? ys. 21.U; 
respectively. p < O.oCH~l) (Table 1. Fig. 1A). This difference in 
mortality in favor of smokers persisted after direct age adjust- 
mcnl ( i l.O?. 9.55; CI 6.9’6 IO l5G vs. 18.6%. 95? CI 15.8s; 
I.11 21.-G. respectively. p < 0.01) (Table 4). However. after 
multivariate analysis adjusting for age and other baseline 
characteristics. thrombolytic therapy and invasive coronary 
procedures (see Methods), the lower 6-month mortality rate in 
smokers was no longer statistically significant (HR 0.84. 95% 
CI 0.54 to 1.30. p = 0.42) (Table 4. Fig. IB). Other variables 
entered (in decreasing order) into the final stepwise model 
!vere congestive heart failure during the hospital period (HR 
3.hl. YSG CI 2.48 to 52-t). age (l-year increment [HR INS. 
YSPi CI 1.03 to l.lffi]), Killip class 111 on admission (HR 2.tlh. 
Y5? CI 1.42 to 3.03). diabetes (HR 1.47. 95% CI 1.06 to 2.02) 
and systolic blood pressure on admission Cl00 mm Hg (HR 
1.83. 95% CI 1.06 to 3.13). 
Comparison ktween smokers with and without thromhol- 
ysis. Among active smokers (n = 367). 181 patients (49%) 
were treated with thrombolysis. The baseline characteristics 
and in-hospital complications (Table 5) of smokers with (n = 
181) and without thrombolysis (n = 186) were comparable. 
Smokers with thrombolysis more often had a Q wave infarction 
and complex ventricular arrhythmias (ventricular tachycardia 
or fibrillation). whereas a previous infarction and paroxysmal 
atrial fibrillation were more frequent among smokers inehgible 
for thrombolysis. Peak CK levels were higher among smokers 
with thrombolysis. Medical treatment and rate of invasive 
coronary procedures performed during the index hospital 
period were similar in both groups except for heparin. which 
was given more frequently to smokers with thrombolysis 
(Table 6). 
Thirty-day mortality rates were similar in smokers with and 
without thrombolysis (6.19 and 5.9%. respectively). The cu- 
Table 3. Management of Smokers and Nonsmtlkcn After Acute 
Mytxardial lnfarctioti 
- 
Smukcn Nonrmcrkcrc 
(il L 3671 111 :- id:) 
---.- . ..- _ -_-__- -__. 
Nil. ‘# N&l. ‘r p VAIC 
--I-- ----_ _ -.-.-. --___I.-.____ .- ^ ----- 
Nilr;wh 3113 s.l .!V? 7’1 0.14 
fkl~-hl1~kL!lS IhS 4s ?h? 41 Il.3 
Ikprrin 291 81 478 lh 0.05 
hpirin 328 UY SIX uu < U.(WIfI 
ACE inhibitors IIN 32 247 39 c II II3 
Calcium antqonists u3 2s 13 20 I.. 0.05 
Diuretic drugs x7 24 3 jtl .I (l.(lull 
DigiK4is ?I h 0: i.3 U.lwY)4 
Thrumfwlyrir IX1 49 .3-l 411 0.lnl5 
Coronary angibgraphy II1 3u lb4 26 (I.11 
I’TCA M 19 70 II 0.uo1 
CAHG !9 5 27 4 0.51 
ACE = angiorcnsincon~,c~ing cnz~: other ahhrcvirritms as in Tahfe 1. 
mulative 6-month crude mortality rate among both groups of 
patients was 7.3% and 8.6%. respectively (p = 0.53 hy log-rank 
test) (Fig. 2). 
Discussion 
The main tinding of the present study is that the seemingly 
better prognosis of smokers after acute myocardial infarc- 
rion may ha attributed to their more favorable risk profile and 
that after adjusting for age and other confounding variahlcs, 
smoking was no longer an independent predictor of better 
prognosis. 
Revious studies. Our findings from a nationwide survey 
are in accordance with some recent clinical trials (10X3--13. In 
the Gruppo Italian0 per lo Studio Della Soprawivenza 
trell’lnfarto Miocardico (GISSL2) study (14) including 9.720 
patients, smokers had a better in-hospital and 6-month post- 
discharge prognosis, which disappeared after multivariate ad- 
justment for clinical variables (age, gender, number of hours 
between symptoms onset to hospital admission, Killip class. 
infarct location, diabetes, hypertension, previous angina, hjdy 
mass index, peak CK levels and number of ECG lcads with ST 
segment elevation). Data from the Myocardial Infarction 
Triage and Intervention (MITi) Project (15). in which two- 
thirds of the patients did not receive thrombolysis. also did not 
identify smoking as an independent predictor of low mortality 
after adjustment (age. reinfarction, congestive heart failure, 
cardiogenic shock and recurrent chest pain). 
In contrast t0 these findings, a number of studies conducted 
in the prethrombolytic and thrombolytic eras foilnd that the 
higher in-hospital mortality among nonsmokeix remained sig- 
nificant even after adjustment for baselint characteristics 
(4-7,16,17). Molstad et al. (5) studied 484 patiepts with a first 
myocardial infarction in the prethrombolytic era. The Oo-day 
mortality of smokers was lower than that of nonsmokers and 
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Table 4. Crude Age-Adjusted Mortality Rats and Multivariate Relative Risk of Dying in Smolicrs and Nonsmokers at 30 Days and 6 Months 
After Acute Mycardial Infarction 
-- 
W-Da:; Mortalit! h-Vunth Mortality 
- 
Smokers Ktrnsmokcn Smokcn N0n3mokzrs 
(II = 3h7) (r, = 633 (ll -367) (II = 632) 
--___- 
so. c; No. (8 p Valur So. 'r SO. Co p V;lluc --_--- 
Age (yr) 
5FO (,I’ .. MI) .I IJh T.4 
;:2 
145 1,s 3’12h 1.4 'iS 
7.4 -.. 
3.6 
51-M) (n = 3lX) .I ')5 11:113 9.7 7.Ll.i I5 Il.1 13.3 
hl-71) (n : 291) SW x.1 28.‘1T 1J.h II 43 11.1 76’192 Iii.ti 
71-M in = 3’) -- 13 IO.3 39.213 18.3 5.39 123 51,213 3.Y 
~SO (n =z 67) 34 37.5 20.5') 33.Y 3.6 37.5 2SY 54.2 
All (II = WI)* " 767 mm,. h.ll Y‘J632 IS.7 i' 1l.ONNl1 z93h7 7.4 I?h hZ? 2l.S i 11.w I 
Agedjustcd (5 ) X.8 13.5 11.11 I&h 
9% Cl (“i) 5.0-12.5 Il.&1h.l) L. -15.11 r5.n-21.4 
Rcbk ridt 0.72 WI 
YC'r (‘I 0.4.LI.20 o.s1-I.!II 
--- 
‘Crude mdrtrlity. tllx W-day mortalih’ odds rittb and h-monrh hazxd rario hy mullivsnalr analysis rhcn comparing thr risk oi dying lwswn smukcn and 
nonsmokcn after adjusting Ra age and vrt&cnt vuirhlcs (SW Methods). Cl = wntiJcncc inlcnal. 
Figure 1. Cumulatiw h-month actuaria! swival curws for smokers 
and nonsmokers: A, Unadjusted Kaplan-Mcicr cunw: : : !~.ooOl 
(log-rank test) for lxwwn-group differences. 8. Uysted survival 
cutve~ predicted from the hc%t selected Cox model. Tb : tielarive risk 
for smokers was not signiticantly different from that ft. rwnsmokers 
(p = (1.42). 
* “i& __.__ _ -__ - \  
----me___ 
0.9 i --__. -~-~-.--.-...___.__________--_____---...- 
TIUE (MONTHS) 
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,Tablc 5. Characteristics, Hospital Complications and Follow-Up 
Mortality in Smokers Treated With and Without Thrombolysis - 
l.Oi, 
AF (~4 
Prior MI 
Prior anfiina 
Hypertension 
Diabetes 
Hypercholcsterolemia 
Farnil) history of CAD 
Prior CABG 
0 wave MI 
On admission 
Sybtnlic BF < 100 mm Hg 
Heart rate >.!Ml bcatslmin 
Killip clarc 211 
Peak CK (Ill) 
ComplicaLms 
PAF 
Advanced AVB 
VLZ’F 
CHFiT’E 
Ca:diogcnic shock 
Recurrent %lI 
Rccurrcnr ischcmia 
Stroke 
Mortality 
30 day 
6 mo 
Thrombolytic Treatment 
Yes 
(n = lR1) (n Z86) -..- 
165 (91) I69 (91) 
51lr II SR + 12 
34 (19) 52 (2U) 
37(21) 35 (19) 
53 (29) 54 (29) 
31(17) 37 (20) 
43 (24) 56 (30) 
36 (20) 43 (23) 
91.5) I i< 1) 
144 (80) I05 (57) 
II(6) IO (5) 0.77 
21jl2) 31 (17) 0.16 
39 I??) 44 (24) 0.63 
1,476 z 1,357 m * 1.16s i 0.001 
4 (3 13 (7) 
18(laJ 11(b)  
33 (18) 11 (6) 
17 (9) 21 (11, 
6 (3 5 (3) 
8 (4) 3 (2) 
17 (9 I9 (10) 
I (< 1) I(< 1) 
11 (6.1) I1 (5.9) 0.95 
13 (7.2) 16 (6.6) 0.61 
p Value 
0.92 
0.46 
0.04 
0.70 
0.76 
0.50 
0.17 
0.45 
0.01 
< O.oool 
n.w 
O.lS 
< n.lm1 
n.s5 
0.73 
0.12 
0.79 
0.99 
Rata presented arc mean value ? SD or number (%I) of patients. Abbrevi- 
ations as in Tables I and 2. 
remained so after adjustment for baseline differences, ECG 
findings, laboratory data and drugs at entrv (relative risk 0.55, 
9% CI 0.33 to 0.93). Sirr.iii;r findings were noted by Kelly et al. 
Table 6. Treatment and Management of Smokers After Acute 
Myc-cardial Infarction According to Thromboiytic Treatment 
Thrombolytic Treatment 
Yes 
(n = ISI) 
No. 8 
(n !:86) 
No. si p V;tluc 
Nitratcs lS6 86 147 79 0.(!7 
Bcwblwkctr H6 JR 79 42 Il.33 
Hcparin 162 YU I35 73 < O.lHMl 
Aspirin 165 92 161 87 0.15 
ACE inhibitors 55 30 63 34 0.48 
Calcium antagonisls 49 26 44 24 0.65 
Diuretic drugs 37 21 50 27 0.15 
Digitalis .6’ 3 1s a 0.05 
Coronary angiography $0 33 51 2s 0.23 
FTCA 37. 21 31 17 0.35 
CABG 10 6 9 5 0.77 
Abbreviations as in Tables 1 and 3. 
Figure 2. Cumulative I-year actuarial survival c~tv~~ for smokers 
tredtcd w~:h and without thrombolysis; p = 0.53 (log-rank test) for 
between-group differences. TX+ = thrombolysis-treated patients; 
‘ITX- = non-thromholysis-treated patients. 
(4) in 2,955 patients (excluding ex-smokers) with an acute 
myocardial infarction, where adjusting for age and other 
variables (blood urea, history of heart failure, angina, myocar- 
dial infarction and pulmonary congestion on admission) re- 
ddced but did not cancel the survival differential favoring 
smokers at 1 month, but did eliminate the mortality differences 
at 6 and 12 months. In two recent large thrombolytic trials 
(6,7), the mortality rate of smokers was lower than that of 
ex-smokers or nonsmokers even after adjustment for baseline 
characteristics. In the study by Barbash et al (61, including 
2,366 nons;nokers, 2,244 ex-smokers and 3,649 active smokers 
from the International Tissue Plasminogen Activator/ 
Streptokinase Mortality Trial, a 1 A-fold increase in in-hospital 
and &month mortality rates was demonstrated for nonsmokers 
after adjusting for baseline characteristics similar to those in 
our study. Similar findings for 30-day mortality, were reported 
from the Global Utilization of Streptokinase and Tissue Plas- 
minogen Activator for Occluded Coronary Arteries (GUSTO-I) 
study (7) in 41,021 patients treated with thrombolysis but not in 
the angiographic substudy (lg). In this subgroup, adjustment 
for clinical and angiographic variables, including coronary 
anatomy, TIM1 grade 3 flow and left ventricular function, 
yielded similar mortality in smokers and nonsmokers (OR 0.93 
for smokers). Similar findings were observed by Grines et al. 
(9) in patients from the Thrombolysis and Angioplasty in 
Myocardial Infarction (TAMI) trials. Smokers had a better 
42day survival after adjustment for baseline clinical variables 
(age, systolic blood pressure, and infarct location) but not after 
adjustment for acute Bngiographic variables, including nvmber 
of diseased ve&els, left ventricular ejection fraction and TIMI 
flow “grade. Thus, a partial explanation for the discrepant 
findings in the different studies may be related to the different 
variables controlled for, in particular the angiographic data. 
Furthermore, because TIMI grade 3 flow is more prevalent 
among smokers after thrombolysis (9-11) and may explain in 
part their improved survival. it may be inappropriate to ctilltrol 
for this variable in the multivariate analysis. 
The most likely explanation for the discrepancy between 
our study and previous studies (6?7.3,18) is that those studies 
did not include consecutive patients as was done in our sumey. 
Rather. they included only patients eligible for a thrombolytic 
trial, who are generally younger and have better baseline 
characteristics and prognosis than those ineligible for throm- 
bolytic therapy. a limitation recognized by Barbash et al. (18) 
for the GUSTO-I study and by others (8). Although our study 
is much smaller than the two aforementioned ones (6.7.18). It 
is based on a consecutive series of unselected patients admitted 
to all coronary care units in Israel during a Z-month period, 
including periphera!, secondary and tertiary hospitals: there- 
fore, its rcstiiis may be more generally applicable to patients 
with acute myoctirdial infarction in the community. 
Possible mechanisms for better outcome in smokers. Sev- 
eral factors may explain the paradox of a seemingly better early 
prognosis of smokers after acute myocardial infarctio?. In our 
study, as in most others, age was a strong independent 
predictor of mortality after myocardial infarction. In the 
Secondary Prevention Reinfarction Israeli Nifedipine Trial 
(SPRINT) Registry (19), a IO-year increment of age was 
associated with a twofold increase in in-hospital mortality. In 
the GUSTO-I trial (7), age was the most significant factor 
influencing 30-day mortality and provided nearly half the 
prognostic information in the multivariate logistic model. In all 
previous studies, smokers experienced myocardial infarction 
at a younger age than nonsmokers (4-6.10,11.13.18,20). In the 
present study, smokers were 10 years younger than nonsmok- 
err. It was also rhown (20) that the adjsstcd age for a first 
nonfatal infarction progressively declined with increasing 
smoking exposure. Thus, the younger age of smokers favors a 
better prognosis during the early phase of acute myocardial 
infarction. 
Smokers also have a more favorable risk profile other than 
age (4-6.9.11.13,18,20). In the present study, the frequency of 
previous infarction, diabetes and hypertension (7.13,21.22) was 
lower among smokers than nonsmokers. 
Smoking is arrhythmogenic (23). increases the incidence of 
late potentials on the signal-averaged ECG and may increase 
the risk of ventricular tachycardia and sudden death (24). 
Therefore, smokers may be more prone to prehospital sudden 
death than r.cnsmokers (25.26). thus artificially reducing the 
in-hospital mortality after acute myocardial infarction. 
The hospit;ll course of nonsmokers was more complicated 
than that of smokers, ,probably due to their older age and 
worse baseline characteristics. In our study. congestive heart 
failure and cardiogenic shock were 3-times more common in 
nonsmokers than in smokers. Nonsmokers more frequently 
received digitalis aitd diuretics. Similar findings were noted in 
previous studies (6,13.18). 
A smaller infarction may lead to better survival in smokers. 
Infarct size was smaller in smokers at %I min after initiation 
of thrombolytic therapy (9,18) but not at hospital dixharge 
(9.10.X). In our study. peak CK levels were similar in smokers 
and ncinsmokers. Similar findings were noted in some s!udies 
(10.20) but not in others ($11). Smokers had a higher fre- 
qucncy of inferior infarction than nonsmokers (5,6.10.11,13.18). 
usuallv associated wi;h a smaller infarction. Nonetheless. even 
if the infarct size is similar in smokers and nonsmokers. 
nonsmokers might have developed more often heart faliure on 
admission and during the hospital course as a result of diastolic 
dysfun&n associated with advanced age. hypertension and 
dia!,rtes. 
In our study, altii;ktrJ were treated more frequently with 
thrombolysis and invasive coronary interventions. probably 
because they were younger and had less contraindications for 
these modes of therapy. Thus, smokers may have benefited 
more from these innovative therapies than nonsmokers. 
Smokers have higher fibrinogen. hematocrit and Factor VII 
levels (9,11.27,28). impaired endothelial function (29) and 
vasospasm (30). predisposing them to thrombus formation and 
myocardial infarction (31). Thus. coronary obstruction in 
smokers might be more thromhogenic and less atherosclerotic 
in nature. A large thrombotic component in smokers may be 
more amenable to vasodilation and thrombolysis and hence to 
more complete reperfusion. leading to improved early infarct- 
related coronary artery flow and less residual atheromatous 
stenosis after thrombolysis. Smokmg precipitates myocardial 
infarction at an earlier age with a lesser degree of coronary 
artcry disease (13,18.32). In the Coronary Artery Surgery 
Study (CASS) registry (33). a negative correlation was noted 
between the extent of cr:onary disease and smoking. McKcnna 
et 31. (31) A.! \ L .; *ii:!! riormal coronary arteries were more 
frcqklrnlii I. bihlo: iir-l .-!n: smokers than nonsmokers after acute 
myocardial infar.W:lir:: ..kgesting a higher rate of vasospastic 
or thrombotic occlusion. Recenti,, several studies pointed out 
that the patency rate (TIM1 grade 3 flow) (9-l 1,18) and lumen 
diameter measured early after thrombolytic therapy are 
greater in smokers than nonsmokers (9). supporting the 
thrombogenic mechanism of infarction among smokers. Con- 
sequently. smokers may have a smaller infarction and may be 
left with less Severe urlderlying narrowing than nonsmokers 
(9). which may explain, at least in part, their better curvival. 
Uniqueness or the study. This survey of consecutive. uns- 
elected. patients with acute myocardial infarction confirms 
observations made earlier in randomized clinical trials. and its 
findings may be morz generally applicable than those obtained 
from selected patients entered in clinical trials. In addition. 
previous studies co!nparcd the prognosis of smokers with that 
o! ncinsmokers after acute myocardial infarction, either in the 
prethromolytic or current thromoolyric era. The present survey 
allowed us to compare the outcome between smokers with and 
without thrombolysis: two groups with similar low risk proliles 
who were otherwise mayaged similarly (Tables 5 and 6). 
Remarkably, mortalit); was similar and low in both groups of 
smokers, suzesting that the favorable outcome of smokers 
after myocardial infarction is probably related lo their better 
baseline characteristics and their younger age. The lack of 
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observed mortality difference between smokers treated versus 
not treated with a thiombolytic agent may also be related to, 
the small numbei of patients in the, present ,sttidy and io the 
!ow mortality rate of young patients with m)ocardial infarction. 
(j5). Our finding is in contrast to that observed in the APSAC 
Intervention Mortality Study, (AIMS) trial (36). where the 
mortality was significantly lowei among smokers trealed with 
thrombolysis than in those not treated with thrombolysis. The 
reason for this discrepancy with our study seems to be due to 
differences in the patient grotips of the two studies. Whereas 
AIMS was a randomized trial in which all patients ~70 years 
old treated within 6 h of symptoms were eligible for thrombol- 
ysis, our nationwide survey included all patients admitted with 
an acute myocardial infarction. Patients not given thrombolysis 
were those who were not eligible for it. It is also conceivable 
that major differences in the use of aspirin, which was much 
lower in the AIMS study than in our study (2% vs. 85%. 
respectively), influenced differently the response to thrombol- 
ysis and the outcome m smokers. 
Limitations of the study. We could not differentiate be- 
tween past-smokers and those who had never smoked. The 
prognosis of ex-smokers after acute myocardial infarction is 
intermediate between that of current smokers and nonsmokers 
(6,7,10,13,14). Thus, the mortality rate in our nonsmoking 
patients may be diluted with ex-smokers and, thus, underesti- 
mated. We cannot exclude the possibility that patients with a 
more adverse risk profile, and thus a worse prognosis, quit 
smoking before the index infarction because of worsening of 
their cardiac condition. 
We do not have information regarding cessation of smoking 
after the acute event, and therefore we could not evaluate its 
impact on outcome after the acute infarction. However, in 
general? posthospital period cessation rates exceed 50% (37). 
The present study includes data on in-hospital complica- 
tions and 6-month mortality but no information on nonfatal 
cardiac even!s during the follow-up period. Even though the 
difference in mortality rates between smokers and nonsmokers 
was noI significant, we cannot exclude the possibility that the 
postdischarge morbidity of smokers may differ from that of 
nonsmokers, especially among those who continued smoking 
(38,39). 
Sum~aq. ‘ine present study in unselected, consecutive 
patients with acute myocardial infarction suggests that smokers 
have an early survival advantage over nonsmokers. However, 
the seemingly better early prognosis could be attributed to the 
younger age, lower risk profile and less eventful hospital course 
of smokers. Smokers present with acute myocardial infarction 
about a decade earlier than past or nonsmokers. Efforts to 
discourage smoking should continue. Larger community-based 
studiec in patients with acute myocardial infarction from 
different countries, assessing &ssical and new risk factors 
[lipoprotein(a), polymorphism in the angiotensin-converting 
enzyme gene] and angiographic and hemostatic data may shed 
further light on the mechanism of the seemingly better prog- 
nosis of smokers. 
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Appendix 
Participating Centers, Directors of Cardiac 
Departments and Responsible Physicians for the 
Israeli Thrombotytic National Survey 
Coordinating cmtcr: Neufeld Cardiac Research Insrirute. Sheba Medical 
Center. Tel Hashomer, Israel 
Partkipating centers, dimctors of ardk dcpmtmcnts and mponsibk 
physicians: A.rsaJ Hat@, Zoifin: Zwi Schlesinger. MD. Hady Faihcl. MD. 
Banilai Me&n/ Cenrer, Aslrkelon: Leonardo Rcisin. MD. Reilinwn Mebaai 
Center, fefarh-Tikwk: Samuel Sclarovsky. MD, Boris Lrasberg. MD. Bikur 
Cholim HospitaL Ierusalem: Shlomo Stem, MD, Andre Keren, MD. Shmuel 
Gottlieh. M’D. End Zion Medical Cenrer, Ha@: Edward Ahinadrr. MD, Ehud 
Goldhammer. MD. Cannrl Hos~iral. Haifa: Basil S. Lewis. MD. David Hallon. 
MD. Moshe Rugclman, MD. dam& Ht.&al and Yin” &&I Clinic, Ha@: 
Abraham Palanl, MD, Chen Shapira. MD. Cenfml Emek Hospital Afub: Tiheriu 
Rosenfeld. MD. Nahum A. Freedherg, MD. Hadassah Ein-Kerem Medical 
Center, Iemsdem: Mertyn S. Go&man, MD, Yonahm Hasin, MD. Hadawh 
hfounf Scqmr. Jemdm: A. Teddy Weiss. MD. Sbimon Rosenheck, MD. 
Hasharon Hospiro/, Perach Tikwh: lzhar Zahavi. MD, Menachem Kanetti. MD. 
Hillel Yafi Hospital Hadem: Benyamin P&d. MD, MSc. Magdalah Rasmi, MD. 
Ichibv Hospital, Soumsky Medical Center, Tel-Aviv: Shlomo Laniado. MD, Arie 
Roth. MD.~Josepirtal Me&Cal Center, Eib: Alen Gelvan, MD. Kaplan Ho&a1 
Rehovof: Avraham Casoi. MD. Michael Oettineer. MD. Luniado HosnirpL 
Maya: Ron Leor, Mb. Meir Hospital Kj~r-Lb;r: Daniel David, MD, frana 
Pauzner, MD. Pariah Hospital, Tiberius: Leonid Rudnik, MD, Shai Reifier, MD. 
Rembarn Medical Center, Ha& Walter Markiewicz. MD, Haim Hammerman. 
MD. Retecca Sief hfedical &er, Safe& Alon T. Mannor. MD. Shaare Zedek 
Medicd Cenfsr, Ierusalrm: Dan Tzivoni. MD, Jonathan Balkin. MD. Shebp 
Mediral Cen!-r. T4 Hashomur Elieser Kaplinsky. MD, Hanoch Hod. MD. 
Snmko hfedto! Cenrer, Beer-Shnr: Alexander Batler. MD. Arie Gilutz. MD. 
IVesrem Galilee Hospiral, Nalraria: Nalhan Roguin, MD. Wdfso Medical Confer, 
Hoion: Yehezkiel Kishon, MD, Michael Krawitzki, ML\. 
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